Albany, NY -- (SBWIRE) -- 08/07/2019 -- Corneal Ulcer Market Insights, Epidemiology and Market Forecast-2028
1. The USA has an incidence of 11 per 100,000 persons for microbial keratitis.
2. The annual incidence of ulcerative keratitis in contact lens wearers is 4–21 per 10,000 daily wear and extended wear soft contact lens wearers.
3. About 50% of the patients who develop infectious keratitis will obtain an optimal vision of 20/60 or worse, and 25% of those patients will attain a final vision of 20/200.
DelveInsight launched a new report on Corneal Ulcer Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Corneal Ulcer market report covers a descriptive overview and comprehensive insight of the Corneal Ulcer epidemiology and Corneal Ulcer market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Corneal Ulcer market report provides insights on the current and emerging therapies.
3. Corneal Ulcer market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Corneal Ulcer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Corneal Ulcer market.
Request for sample pages
"HIV-infected individuals have a much higher incidence of corneal ulceration."
A corneal ulcer is an open sore, which forms on the cornea. Infection usually causes it. By wearing contact lenses for too long can cause small injuries to the eye or erosion and eventually lead to infections. It can be caused by several micro-organisms such as bacteria, viruses, fungi or even parasites. The expanded range of antibiotics has made Corneal Ulcer treatment easy.
Corneal Ulcer treatment begins with moxifloxacin or gatifloxacin for small ulcers and fortified (higher than stock concentration) antibiotic drops, such as tobramycin and cefazolin, for more significant ulcers, particularly those that are near the centre of the cornea. A common viral infection that is Herpes simplex is treated with trifluridine, ganciclovir, valacyclovir, or acyclovir. The topical antifungal drops, e.g., natamycin, amphotericin B, and sometimes voriconazole (which is less effective) are used for fungal infections treatment. Deep infections may require the addition of oral voriconazole, ketoconazole, fluconazole and itraconazole.
One of the effective antibiotics in Corneal Ulcer treatment has been ciprofloxacin. Ciprofloxacin belongs to a class of drugs called quinolone antibiotics. Its mechanism is to halt the growth of bacteria. It covers all common corneal pathogens and has the edge over a combination therapy of aminoglycosides and cephalosporins in that ciprofloxacin is effective against many strains of aminoglycoside resistant Pseudomonas and methicillin-resistant Staphylococcus aureus (MRSA).
The global Corneal Ulcer therapeutics market is further expected to increase by the major drivers such as rising Incident population, technological advancements, and upcoming therapies in the forecast period [2019–2028].
Drugs covered
1. Recombinant human Nerve Growth Factor (rhNGF)
2. Remlarsen
And many others
The key players in Corneal Ulcer market are:
1. Dompe
2. miRagen Therapeutics
And many others
Table of contents
1. Report Introduction
2. Corneal Ulcer Market Overview at a Glance
3. Corneal Ulcer Disease Background and Overview
4. Corneal Ulcer Epidemiology and Patient Population (7MM)
5. Corneal Ulcer Country- Wise Epidemiology
5.1. United States
5.2. EU5 Countries
5.3. Germany
5.4. France
5.5. Italy
5.6. Spain
5.7. United Kingdom
5.8. Japan
6. Corneal Ulcer Treatments & Medical Practices
7. Corneal Ulcer Marketed Drugs
7.1 Cenegermin: Dompe
8. Corneal Ulcer Emerging Therapies
8.1. Key Cross Competition
8.2. rhNGF: Dompe
9. Corneal Ulcer Market Size
10. 7MM: Country-Wise Market Analysis
11. United States Market Size
12. EU5 Market Size
12.1. Germany Market Size
12.2. France Market Size
12.3. Italy Market Size
12.4. Spain Market Size
12.5. United Kingdom Market Size
13. Japan Market Size
14. Market Drivers
15. Market Barriers
16. Corneal Ulcer Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight